Last updated: February 24, 2026
What is NDC 10542-0014?
NDC 10542-0014 refers to Aptivus (tipranavir), an antiretroviral medication used in combination therapy for HIV-1 infections. It is manufactured by Boehringer Ingelheim. Tipranavir is a non-peptidic protease inhibitor, often prescribed for salvage therapy in patients with multidrug-resistant HIV.
Market Overview
Current Market Size
The HIV treatment market globally was valued at approximately $31 billion in 2022, with protease inhibitors representing about 20% of this segment. The specific niche for tipranavir targets patients with multidrug-resistant HIV strains, representing a smaller subset within the overall protease inhibitor market.
Patient Demographics
- Estimated 1.2 million people in the U.S. living with HIV/AIDS.
- About 15% are considered to have multidrug-resistant HIV strains, qualifying for third-line therapies like tipranavir.
- The global prevalence aligns proportionally with the U.S., translated to roughly 180,000 patients potentially eligible for tipranavir therapy.
Competitive Landscape
Key competitors include:
- Darunavir (Prezista) by Janssen
- Atazanavir (Reyataz) by Johnson & Johnson
- Lopinavir/Ritonavir (Kaletra) by AbbVie
- Other salvage therapy agents such as Fosamprenavir and Saquinavir
Tipranavir's market share has declined due to newer agents with improved efficacy and tolerability profiles, but it remains vital for multidrug-resistant cases.
Regulatory Status
- Approved by FDA in 2005 for use in combination with other antiretrovirals.
- Approved in Europe and other markets, with varying indications.
- Patent protection expired or is due to expire in 2025, affecting exclusivity and pricing.
Price Trends and Projections
Historical Pricing
- Retail price (wholesale acquisition cost, WAC): approximately $1,800 per 30-tablet bottle in the U.S. (2022).
- Back then, the list price ranged from $6,200 to $7,000 per month for a typical regimen.
Recent Market Dynamics
- Price discounts and managed care negotiations have reduced patient out-of-pocket costs.
- Generic versions or biosimilar processes are not yet available as of 2023, owing to patent expiry date (~2025).
Projected Pricing in 2023-2028
| Year |
Estimated WAC Price per 30 tablets |
Key Factors |
| 2023 |
$1,600 |
Price pressure from generics anticipated post-2025. |
| 2024 |
$1,400 |
Patent expiry approaches, potential biosimilar entry preparations. |
| 2025 |
$800 - $1,000 |
Patent expiration, biosimilar/ generic availability likely. |
| 2026+ |
$500 - $800 |
Increased competition, market share shifts. |
Price Drivers
- Patent expiration poised for 2025 affects exclusivity.
- Biosimilar or generic entry expected to decrease prices by 50% or more.
- Insurance and reimbursement policies influence actual payer costs.
- Newer agents with improved tolerability could further erode market share and pricing for tipranavir.
Regulatory and Patent Landscape
| Year |
Event |
Impact |
| 2023 |
Patent protections remain in key markets |
Maintains pricing power, delays generics entry. |
| 2025+ |
Patent expiry in major markets |
Biosimilars, generics may reduce prices significantly. |
| 2023-2028 |
Regulatory filings for biosimilars and generics |
Market entry expected, increasing price competition. |
Market Outlook Summary
- The market for tipranavir is shrinking due to competition, with pricing declining as patent exclusivity ends.
- Peak pricing is around $1,600 per 30-day supply; post-patent expiry estimates project prices falling below $1,000.
- The number of eligible patients remains steady but is a niche within HIV therapy.
Key Takeaways
- NDC 10542-0014 (tipranavir) remains a salvage therapy for multidrug-resistant HIV, with a declining market share.
- The current U.S. wholesale price is approximately $1,600 per bottle.
- Price projections anticipate a sharp decline post-2025, driven by patent expiration and biosimilar entry.
- The total addressable market is roughly 180,000 patients globally, with a growing focus on newer agents.
- Competition and regulatory trends will likely commoditize tipranavir, with significant price erosion over the next 3-5 years.
FAQs
1. When will patent expiry likely occur for tipranavir?
Patent expiry is anticipated in 2025 in major markets, enabling biosimilar or generic competition.
2. How will biosimilar entry affect pricing?
Biosimilars or generics could reduce price by 50% or more, depending on market uptake and regulatory approvals.
3. What are the major alternatives to tipranavir?
Darunavir, atazanavir, and other salvage agents are key competitors, often offering better tolerability and efficacy.
4. What is the current global market size for tipranavir?
Approximately 180,000 eligible patients, primarily with multidrug-resistant HIV.
5. How does insurance coverage influence net prices?
Reimbursement policies, negotiated discounts, and patient assistance programs significantly impact actual cost to payers.
References:
- IQVIA. (2022). HIV Market Insights.
- U.S. Food and Drug Administration. (2005). Approval letter for Aptivus.
- IMS Health. (2022). Protease inhibitors market report.
- European Medicines Agency. (2022). Summary of Product Characteristics for tipranavir.
- Patents and Drug Approvals Database. (2023). Patent expiration dates for tipranavir.
[1] FDA. (2005). Aptivus (tipranavir) approval letter.
[2] IQVIA. (2022). HIV drugs market analysis.
[3] EMA. (2022). Tipranavir summary.
[4] USPTO. (2023). Patent expiration analysis.
